查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610203

肿瘤精准医学市场：按类型、癌症类型、最终用途分类 - 2025-2030 年全球预测

Oncology Precision Medicine Market by Type (Cell & Gene Therapy, Inhibitor drugs, Monoclonal Antibodies), Cancer Type (Breast Cancer, Cervical Cancer, Colorectal Cancer), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

肿瘤精准医疗市场2023年估值为73.4亿美元，预计2024年将达到76.7亿美元，复合年增长率为9.10%，到2030年将达到135.1亿美元。

肿瘤精准医疗是指利用基因组、生物标记和其他分子讯息，根据每个患者的癌症特征制定治疗方案，以优化治疗效果。精准医疗的需求是改善治疗结果、减少副作用并简化医疗服务。其应用范围涵盖诊断、治疗监测和治疗创新，对癌症中心、医院和研究机构产生重大影响。最终用途范围正在迅速扩大，包括个人化癌症疫苗、标靶治疗和下一代定序技术。影响市场的主要成长要素包括基因组学的技术进步、癌症盛行率的增加、政府的有利倡议以及製药和生物技术公司之间不断加强的伙伴关係。该领域最近的机会在于整合人工智慧和巨量资料分析以提高预测准确性，以及开发具有成本效益的下一代定序方法以扩大可及性。精准医学的应用还有可能不仅限于常见癌症，还包括罕见癌症和尚未充分治疗的癌症类型。

主要市场统计
基准年[2023] 73.4亿美元
预计年份 [2024] 76.7亿美元
预测年份 [2030] 135.1亿美元
复合年增长率（%） 9.10%

然而，先进诊断的高成本、资料管理的复杂性、监管障碍以及需要熟练的专业人员解释复杂的遗传资讯等挑战对 Masu 的市场成长构成了重大限制。该领域的创新可以集中于开发强大的生物资讯解决方案、增强对癌症生物学的理解以及建立适应性临床试验设计。此外，与科技公司的合作可以增强资料驱动的洞察力，以改善患者分层和个人化治疗方法。市场仍然高度活跃，竞争刺激了新诊断和治疗方法的进步。为了利用新兴趋势，相关人员应投资合作研究，专注于以患者为中心的方法，并积极与政策制定者合作，以建立有利的法律规范，以改善日常临床实践。和整合精准肿瘤学。

市场动态：揭示快速发展的肿瘤精准医学市场的关键市场洞察

肿瘤精准医疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界人口癌症发生率上升
    • 政府推动精准医疗的倡议
    • 更多采用基因检测来加强精准医疗
  • 市场限制因素
    • 肿瘤精准医学治疗的报销限制
  • 市场机会
    • 持续研究和开发癌症治疗的个人化医疗
    • 肿瘤组织和液态切片临床下一代定序的进展
  • 市场挑战
    • 围绕精准肿瘤学的复杂法律规范

波特五力：驾驭肿瘤精准医学市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肿瘤精准医疗市场的外在影响

外部宏观环境因素在塑造肿瘤精准医疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解肿瘤精准医疗市场的竞争格局

对肿瘤精准医学市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵肿瘤精准医疗市场供应商绩效评估

FPNV 定位矩阵是评估肿瘤精准医学市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划肿瘤精准医疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对肿瘤精准医学市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界人口癌症发生率上升
      • 政府推动精准医疗的倡议
      • 扩大基因检测的引入，加强精准医疗
    • 抑制因素
      • 肿瘤精准医学治疗的报销有限
    • 机会
      • 持续研究和开发癌症治疗的个人化医疗
      • 肿瘤组织和液态生物检体临床次世代定序的进展
    • 任务
      • 围绕精准肿瘤学的复杂法规结构
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章肿瘤精准医学市场：依类型

  • 细胞/基因治疗
  • 抑制剂
  • 单株抗体

第七章依癌症类型分類的肿瘤精准医学市场

  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第八章肿瘤精准医学市场：依最终用途分类

  • 医院和诊断实验室
  • 製药和生物技术公司

第九章美洲肿瘤精准医疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太肿瘤精准医疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲肿瘤精准医疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • AstraZeneca PLC
  • BJ Madan & Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • Genome Medical boasts
  • GSK PLC
  • IQVIA Inc.
  • Laboratory Corporation of America Holding
  • llumina, Inc.
  • Merck KGaA
  • Novartis AG
  • OneOme, LLC
  • Pfizer Inc.
  • Rain Oncology Inc.
  • Relay Therapeutics
  • Sanofi SA
  • Strata Oncology, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Variantyx, Inc.
  • Xilis, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.67 billion in 2024, and is projected to grow at a CAGR of 9.10%, to USD 13.51 billion by 2030.

Oncology precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient's cancer, leveraging genomic, biomarker, and other molecular information to optimize therapeutic efficacy. The necessity of precision medicine arises from its ability to improve treatment outcomes, reduce adverse effects, and enhance the efficiency of healthcare delivery. Its applications span across diagnosis, treatment monitoring, and therapeutic innovation, significantly impacting cancer centers, hospitals, and research institutions. The end-use scope is rapidly expanding to include personalized cancer vaccines, targeted therapies, and next-generation sequencing technologies. Key growth factors influencing the market include technological advancements in genomics, increasing prevalence of cancer, favorable government initiatives, and rising partnerships between pharmaceutical firms and biotech companies. Recent opportunities in this field lie in integrating artificial intelligence and big data analytics to enhance predictive accuracy and developing cost-effective next-generation sequencing methods to widen accessibility. There's also potential in expanding precision medicine applications beyond common cancers into rare and underserved cancer types.

KEY MARKET STATISTICS
Base Year [2023] USD 7.34 billion
Estimated Year [2024] USD 7.67 billion
Forecast Year [2030] USD 13.51 billion
CAGR (%) 9.10%

However, challenges such as high costs of advanced diagnostics, complexity in data management, regulatory hurdles, and a need for skilled professionals to interpret complex genetic information pose significant limitations to market growth. Innovation in this sector could focus on developing robust bioinformatics solutions, enhancing the understanding of cancer biology, and creating adaptive clinical trial designs. Furthermore, engaging in collaborations with technology firms could enhance data-driven insights, improving patient stratification and personalized treatment regimens. The market remains highly dynamic, with competition spurring advancements in novel diagnostics and therapeutic methodologies. To capitalize on emerging trends, stakeholders should invest in collaborative research, focus on patient-centric approaches, and actively engage with policymakers to facilitate favorable regulatory frameworks, thus driving broader adoption and integration of precision oncology in routine clinical practice.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Precision Medicine Market

The Oncology Precision Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of cancer among the global population
    • Government initiatives to promote precision medicine
    • Increasing adoption of genetic testing to enhance precision medicine
  • Market Restraints
    • Limited reimbursement available for oncology precision medicine treatment
  • Market Opportunities
    • Ongoing R&D to develop personalized medicine to treat cancer
    • Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
  • Market Challenges
    • Complex regulatory framework surrounding precision oncology

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Precision Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Precision Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Precision Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Precision Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Precision Medicine Market

A detailed market share analysis in the Oncology Precision Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Precision Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Precision Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Precision Medicine Market

A strategic analysis of the Oncology Precision Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, B. J. Madan & Co., Bayer AG, Bristol-Myers Squibb Company, Cepheid Inc., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, Genome Medical boasts, GSK PLC, IQVIA Inc., Laboratory Corporation of America Holding, llumina, Inc., Merck KGaA, Novartis AG, OneOme, LLC, Pfizer Inc., Rain Oncology Inc., Relay Therapeutics, Sanofi S.A., Strata Oncology, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Variantyx, Inc., and Xilis, Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell & Gene Therapy, Inhibitor drugs, and Monoclonal Antibodies.
  • Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End-use, market is studied across Hospitals & Diagnostic Laboratories and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of cancer among the global population
      • 5.1.1.2. Government initiatives to promote precision medicine
      • 5.1.1.3. Increasing adoption of genetic testing to enhance precision medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement available for oncology precision medicine treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to develop personalized medicine to treat cancer
      • 5.1.3.2. Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory framework surrounding precision oncology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Precision Medicine Market, by Type

  • 6.1. Introduction
  • 6.2. Cell & Gene Therapy
  • 6.3. Inhibitor drugs
  • 6.4. Monoclonal Antibodies

7. Oncology Precision Medicine Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cervical Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Prostate Cancer

8. Oncology Precision Medicine Market, by End-use

  • 8.1. Introduction
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Pharmaceutical & Biotechnology Companies

9. Americas Oncology Precision Medicine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncology Precision Medicine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Precision Medicine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. B. J. Madan & Co.
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Cepheid Inc.
  • 7. Eli Lilly & Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. Genome Medical boasts
  • 10. GSK PLC
  • 11. IQVIA Inc.
  • 12. Laboratory Corporation of America Holding
  • 13. llumina, Inc.
  • 14. Merck KGaA
  • 15. Novartis AG
  • 16. OneOme, LLC
  • 17. Pfizer Inc.
  • 18. Rain Oncology Inc.
  • 19. Relay Therapeutics
  • 20. Sanofi S.A.
  • 21. Strata Oncology, Inc.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Thermo Fisher Scientific, Inc.
  • 24. Variantyx, Inc.
  • 25. Xilis, Inc.

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY PRECISION MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY PRECISION MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023